Abstract
Worldwide more than 350,000 patients will be diagnosed with oral cancer this year; however, the survival of patients with oral cancer has not changed significantly over the last 30 years. Recent reports have demonstrated that epithelial-mesenchymal transition (EMT) not only contributes to cancer cell invasion and metastasis but it is also associated with treatment resistance. In this review, we will examine the data demonstrating the role of EMT in oral cancer and the extent to which it contributes to poor response to current therapeutic modalities. We will also examine the interplay between EMT and microRNAs and review the role of microRNAs in modulating resistance of oral cancer cells to current therapeutic modalities. Similarly, we will review how EMT contributes to the generation and maintenance of stem cells and examine the role of stem cells in oral cancer recurrence and in modulating treatment resistance. Finally, we will examine how EMT is involved in fibrosis, which can limit delivery of therapeutic agents to cancer cells. Overall, this review will summarize our understanding of how EMT contributes to oral cancer progression and identify additional therapeutic targets that may help to reduce the morbidity and mortality associated with oral cancer.
Keywords: Epithelial-mesenchymal transition, microRNA, stem cells, fibrosis, oral cancer, treatment resistance, chemotherapy, E-cadherin, metalloproteinas, cytokine interleukin
Current Cancer Therapy Reviews
Title: Understanding Epithelial-Mesenchymal Transition may Reveal Novel Therapeutic Targets for Oral Squamous Cell Carcinoma
Volume: 7 Issue: 2
Author(s): Hidayatullah G. Munshi and M. Sharon Stack
Affiliation:
Keywords: Epithelial-mesenchymal transition, microRNA, stem cells, fibrosis, oral cancer, treatment resistance, chemotherapy, E-cadherin, metalloproteinas, cytokine interleukin
Abstract: Worldwide more than 350,000 patients will be diagnosed with oral cancer this year; however, the survival of patients with oral cancer has not changed significantly over the last 30 years. Recent reports have demonstrated that epithelial-mesenchymal transition (EMT) not only contributes to cancer cell invasion and metastasis but it is also associated with treatment resistance. In this review, we will examine the data demonstrating the role of EMT in oral cancer and the extent to which it contributes to poor response to current therapeutic modalities. We will also examine the interplay between EMT and microRNAs and review the role of microRNAs in modulating resistance of oral cancer cells to current therapeutic modalities. Similarly, we will review how EMT contributes to the generation and maintenance of stem cells and examine the role of stem cells in oral cancer recurrence and in modulating treatment resistance. Finally, we will examine how EMT is involved in fibrosis, which can limit delivery of therapeutic agents to cancer cells. Overall, this review will summarize our understanding of how EMT contributes to oral cancer progression and identify additional therapeutic targets that may help to reduce the morbidity and mortality associated with oral cancer.
Export Options
About this article
Cite this article as:
G. Munshi Hidayatullah and Stack M. Sharon, Understanding Epithelial-Mesenchymal Transition may Reveal Novel Therapeutic Targets for Oral Squamous Cell Carcinoma, Current Cancer Therapy Reviews 2011; 7 (2) . https://dx.doi.org/10.2174/1573394711107020104
DOI https://dx.doi.org/10.2174/1573394711107020104 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Genetic Variants in Genes Involved in Mechanisms of Chemoresistance to Anticancer Drugs
Current Cancer Drug Targets Cytology for the Detection of Early Recurrence of Gynecologic Cancer in the Vaginal Vault
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Role of Protein Kinase C-alpha (PKC-α) in Cancer and its Modulation by the Novel PKC-α-Specific Inhibitor Aprinocarsen
Current Pharmaceutical Design Near-infrared Light Activatable Multimodal Gold Nanostructures Platform: An Emerging Paradigm for Cancer Therapy
Current Cancer Drug Targets EGFR-Targeting Monoclonal Antibodies in Head and Neck Cancer
Current Cancer Drug Targets Expression and Prognostic Relevance of GAGE1 and XAGE1 Cancer/Testis Antigens in Head and Neck Squamous Cell Carcinoma
Current Molecular Medicine New Potential Pharmaceutical Applications of Hypericum Species
Mini-Reviews in Medicinal Chemistry Natural compound-derived epigenetic regulators targeting epigenetic readers, writers and erasers
Current Topics in Medicinal Chemistry Liposomes: An Emerging Approach for the Treatment of Cancer
Current Pharmaceutical Design Neuroendocrine Tumors of the Lung: Hystological Classification, Diagnosis, Traditional and New Therapeutic Approaches
Current Medicinal Chemistry Recent Patents on Light Based Therapies: Photodynamic Therapy, Photothermal Therapy and Photoimmunotherapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Wnt1 Inducible Signaling Pathway Protein 1 (WISP1) Blocks Neurodegeneration through Phosphoinositide 3 Kinase/Akt1 and Apoptotic Mitochondrial Signaling Involving Bad, Bax, Bim, and Bcl-xL
Current Neurovascular Research Emerging Role of the Ubiquitin-proteasome System as Drug Targets
Current Pharmaceutical Design Imiquimod 5% Cream Use in Dermatology, Side Effects and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery Curcumin in Combined Cancer Therapy
Current Pharmaceutical Design P53 Family: At the Crossroads in Cancer Therapy
Current Medicinal Chemistry Diagnostic and Therapeutic Applications of Recombinant Antibodies:Targeting the Extra-Domain B of Fibronectin, A Marker of Tumor Angiogenesis
Current Pharmaceutical Design Mitochondrial Drug Targets in Cell Death and Cancer
Current Pharmaceutical Design Prognostic and Predictive Biomarkers in Colorectal Cancer. From the Preclinical Setting to Clinical Practice
Current Cancer Drug Targets The Quest for Surrogate Markers of Angiogenesis: A Paradigm for Translational Research in Tumor Angiogenesis and Anti- Angiogenesis Trials
Current Molecular Medicine